Magrolimab was 47's lead product. Good for 47 to have perhaps benefitted by the acquisition more than they might have benefitted by remaining independent.
But I see absolutely no comparison to lenz and Humanigen, and I expect that we will benefit far more without a Gilead alliance. I think Durrant and Dale are entrepreneurs, and that's a fire that you just can't put out once it starts burning.
I want our revenue to light up our earnings per share, and our most effective way to realize that is to keep away from large market cap entities, and let the shareholders be the beneficiaries of the company's success.
News 
Market Data 
Discover 
AI
